RT Journal Article
T1 Mediterranean diet and diabetes risk in a cohort study of individuals with prediabetes: propensity score analyses
A1 Cea Soriano, Lucía
A1 Pulido Manzanero, José
A1 Franch Nadal, Josep
A1 Santos Sancho, Juana María
A1 Mata Cases, Manel
A1 Díez Espino, Javier
A1 Ruiz García, Antonio
A1 Regidor Poyatos, Enrique
AB AimsRandomized controlled trials have demonstrated the efficacy of several dietary patterns plus physical activity to reduce diabetes onset in people with prediabetes. However, there is no evidence on the effect from the Mediterranean diet on the progression from prediabetes to diabetes. We aimed to evaluate the effect from high adherence to Mediterranean diet on the risk of diabetes in individuals with prediabetes.MethodsProspective cohort study in Spanish Primary Care setting. A total of 1184 participants with prediabetes based on levels of fasting plasma glucose and/or glycated hemoglobin were followed up for a mean of 4.2 years. A total of 210 participants developed diabetes type 2 during the follow up. Hazard ratios of diabetes onset were estimated by Cox proportional regression models associated to high versus low/medium adherence to Mediterranean diet. Different propensity score methods were used to control for potential confounders.ResultsIncidence rate of diabetes in participants with high versus low/medium adherence to Mediterranean diet was 2.9 versus 4.8 per 100 persons-years. The hazard ratios adjusted for propensity score and by inverse probability weighting (IPW) had identical magnitude: 0.63 (95% confidence interval, 0.43–0.93). The hazard ratio in the adjusted model using propensity score matching 1:2 was 0.56 (95% confidence interval, 0.37–0.84).ConclusionsThese propensity score analyses suggest that high adherence to Mediterranean diet reduces diabetes risk in people with prediabetes.
PB Wiley
SN 0742-3071
YR 2021
FD 2021-12-06
LK https://hdl.handle.net/20.500.14352/4721
UL https://hdl.handle.net/20.500.14352/4721
LA eng
NO CRUE-CSIC (Acuerdos Transformativos 2021)
NO Sanofi and Novartis
DS Docta Complutense
RD 28 abr 2024